Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Bevacizumab in Advanced HER2- Breast Cancer
NCT02802098Phase 1Completed
- Sponsor
- Spanish National Cancer Research Centre
- Start
- May 2016
- Primary completion
- Jun 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in breast cancer, sponsored by Spanish National Cancer Research Centre. Primary endpoints: Peripheral blood mononuclear cells subpopulations, Progression-Free Survival up to 12 weeks and 1 more. Started May 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02802098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802098.